13138-74-4Relevant articles and documents
Design, synthesis, DNA-binding and cytotoxicity evaluation of new potential combilexines
Hotzel, Christian,Marotto, Annalisa,Pindur, Ulf
, p. 367 - 378 (2002)
Combilexines, compounds in which a DNA intercalator is linked to a minor groove binding component, interact with the DNA in a sequence specific manner to yield in most cases compounds with anticancer activity. A series of new compounds closely related to netropsin in which the two components were linked by an amide group was synthesised as potential combilexines. As some of these compounds showed cytotoxic activity in vitro, an attempt was made to rationalise their mechanism of action. The DNA binding characteristics of the carboxamides were evaluated by thermal denaturation experiments and by ethidium bromide displacement assay. Their ability to inhibit the topoisomerase I was also determined. It was concluded that the new compounds were only weak DNA ligands although able in some cases to inhibit topoisomerase I.
A sweet origin for the key congocidine precursor 4-acetamidopyrrole-2- carboxylate
Lautru, Sylvie,Song, Lijiang,Demange, Luc,Lombès, Thomas,Galons, Hervé,Challis, Gregory L.,Pernodet, Jean-Luc
, p. 7454 - 7458 (2012/09/21)
Feeding (Streptomyces) frenzy: Natural products belonging to the pyrrolamide family are defined by their pyrrole-2-carboxamide moiety. 4-acetamidopyrrole-2-carboxylate is identified as the key pyrrolamide congocidine precursor (see scheme) through feeding studies using Streptomyces ambofaciens. The biosynthetic pathway of congocidine starts with the carbohydrate N-acetylglucosamine and involves carbohydrate-processing enzymes. Copyright
PYRROLO [1, 2-B] PYRIDAZINE DERIVATIVES AS JANUS KINASE INHIBITORS
-
Page/Page column 104, (2011/02/24)
The invention provides compounds of formula l: ( I ) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for suppressing an immune response or treating cancer or a hematologic malignancy using compounds of formula I.